Germline BRCA2 mutations foster resistance to CDK4/6 inhibitors in breast cancer

npj Precision Oncology 2026 Open access

Read full text
Authors: Lukas Bolini, Flavie Naulin, Neil Johnson, Lorenzo Galluzzi
DOI: 10.1038/s41698-026-01481-3
Cited by: 1
References: 8

Abstract

While CDK4/6 inhibitors have revolutionized the management of patients with breast cancer, the clinical benefits of these agents remain limited by resistance mechanisms. Recent findings demonstrate that germline BRCA2 mutations foster resistance to CDK4/6 inhibitors via RB1 loss-of-function alterations that (in some cases) are acquired through persistent homologous recombination defects.

Fields of Study & Subjects

BRCA gene mutations in cancer Advanced Breast Cancer Therapies PARP inhibition in cancer therapy

Publication details

Journal / source
npj Precision Oncology
Publisher
Springer Science and Business Media LLC
Volume
10
Issue
1
Publication date
12 May 2026
Language
EN